Brookline Capital Management Upgrades I-Mab (NASDAQ:IMAB) to Strong-Buy

I-Mab (NASDAQ:IMAB) was upgraded by equities research analysts at Brookline Capital Management to a “strong-buy” rating in a note issued to investors on Thursday,Zacks.com reports.

Separately, HC Wainwright reissued a “buy” rating and issued a $8.00 price target on shares of I-Mab in a research note on Friday, November 15th.

I-Mab Trading Up 2.9 %

Shares of IMAB opened at $0.93 on Thursday. The stock has a 50 day moving average of $0.99 and a 200-day moving average of $1.08. I-Mab has a 52 week low of $0.84 and a 52 week high of $2.00.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the company. Millennium Management LLC increased its holdings in shares of I-Mab by 763.1% during the 4th quarter. Millennium Management LLC now owns 97,749 shares of the company’s stock valued at $83,000 after acquiring an additional 86,424 shares during the last quarter. Cantor Fitzgerald L. P. acquired a new position in shares of I-Mab during the 4th quarter valued at about $119,000. BNP Paribas Financial Markets bought a new stake in I-Mab during the 4th quarter valued at approximately $93,000. XTX Topco Ltd boosted its stake in I-Mab by 140.8% during the 3rd quarter. XTX Topco Ltd now owns 43,039 shares of the company’s stock valued at $53,000 after purchasing an additional 25,163 shares during the period. Finally, Garden State Investment Advisory Services LLC bought a new stake in I-Mab during the 3rd quarter valued at approximately $179,000. 38.38% of the stock is owned by institutional investors and hedge funds.

I-Mab Company Profile

I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics in the fields of immuno-oncology and immuno-inflammation diseases primarily in the United States. It is developing Uliledlimab, a CD73 neutralizing antibody, which is in Phase 2 clinical trial for the treatment of solid tumors; Givastomig, a bi-specific antibody that is in Phase 1 clinical trial for the treatment of gastric and other cancers; and Ragistomig, a programmed cell death ligand-based tumor-dependent T cell engager, which is in Phase 1 clinical trial for the treatment of for solid tumors.